Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00168038
Status:
COMPLETED
Last Update Posted:
2011-11-23
First Post:
2005-09-12
Brief Title:
Treatment of Chronic Immune Thrombocytopenic Purpura ITP With Intravenous Immunoglobulin IgPro10
Sponsor:
CSL Behring
Organization:
CSL Behring
Study Overview
Official Title:
An Open-label Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura ITP
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura ITP The main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to 50 x 109L
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-000537-11 | EUDRACT_NUMBER | None | None |